All In Biotech

Drug Trial Radar · NCT07728188

A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

A Phase 3, Multicenter, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etentamig in Combination With Pomalidomide Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (2L+ RRMM)

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 520 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

520

Planned (sponsor's estimate)

Start

Oct 20, 2026

Primary completion

Feb 2033

Study completion Feb 2033

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Jul 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multiple myeloma (MM) is a plasma cell malignancy characterized by the proliferation of clonal plasma cells in the bone marrow. The disease primarily localizes to the bones and bone marrow, with resultant cytopenias, bone pain, fractures, infections, hypercalcemia, and renal failure. This study aims to evaluate the safety and change in disease activity of etentamig in combination with pomalidomide compared with standard available therapies in participants with relapsed or refractory multiple myeloma who have received 1-3 prior lines of treatment, including lenalidomide. Etentamig is an investigational drug being developed for the treatment of relapsed or refractory multiple myeloma. This is a randomized, open-label study. The study will include a safety run-in portion and a randomized portion. The safety run-in participants will receive etentamig in combination with pomalidomide. The randomized portion of the study participants will receive either etentamig with pomalidomide or Standard Available Therapies (SATs). Approximately 520 participants will be enrolled in the study at approximately 200 sites worldwide. Prior to initiation of the randomized portion of the study, the safety run-in will be conducted in which participants will receive etentamig injections plus oral pomalidomide. Following review of the safety run-in data and per protocol-defined criteria, the study will advance to the randomized portion where participants will be randomized to receive either etentamig injections plus oral pomalidomide or investigator's choice of SAT: SC daratumumab, oral pomalidomide, and oral/ IV dexamethasone (DPd); SC daratumumab, IV carfilzomib, and oral/IV dexamethasone (DKd); or SC teclistamab monotherapy. The total study duration is approximately 75 months There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a hospital or clinic. The effects of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Relapsed or Refractory Multiple Myeloma

Interventions

  • EtentamigDrug

    Injection

  • PomalidomideDrug

    Oral

  • DaratumumabDrug

    Injection

  • DexamethasoneDrug

    Oral or Injection

  • CarfilzomibDrug

    Injection

  • TeclistamabDrug

    Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Run-In: Number of Participants With Adverse Events (AE)sTime frame: Up to Approximately 75 Months
  2. Randomized Portion: Complete Response (CR) or Better Rate Per Independent Review Committee (IRC) AssessmentTime frame: Up to Approximately 75 Months
  3. Randomized Portion: Progression-Free Survival (PFS) Per Independent Review Committee (IRC) AssessmentTime frame: Up to Approximately 75 Months

Locations

7 sites in 4 countries. Site status is shown where the registry gives one.

  • Community Cancer Trials Of Utah /ID# 286936

    Ogden, Utah · Recruiting

  • Shaare Zedek Medical Center /ID# 286845

    Jerusalem, Israel · Recruiting

  • University Hospital Kyoto Prefectural University of Medicine /ID# 283236

    Kyoto, Kyoto, Japan · Recruiting

  • Miyagi Cancer Center /ID# 283367

    Natori-shi, Miyagi, Japan · Recruiting

  • Tokyo Metropolitan Komagome Hospital /ID# 283370

    Bunkyo Ku, Tokyo, Japan · Recruiting

  • Yamagata University Hospital /ID# 283378

    Yamagata, Yamagata, Japan · Recruiting

  • China Medical University Hospital /ID# 282988

    Taichung, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.